Contact tracing was provided for 683/781 (87%, regional range 57-97%) cases, and identified 997 traceable contacts of whom 511 (51%) were seen, short of the recommended standard of 60%. However, the performance range for this standard was 26-70%, with seven regions achieving 60% or more. Of 511, 215 (42%, range 3-73%) contacts had syphilis. Treatment completion was recorded for 691 (88%, range 71-100%) cases, and resolution of lesions for 348/469 (74%, range 40-96%) cases. Nationally, 419/764 (55%, range 37-70%) cases were recorded as having a two dilution (four-fold) or greater decrease in non-treponemal test titre within 3-6 months after treatment; not achieving this titre decrease was mainly attributable to non-attendance for follow-up and failure of titre levels to fall. Followup of infectious syphilis in UK genitourinary medicine clinics is poor and falls far short of that recommended by National Guidelines. Only 16 (2%) cases had followup at intervals approximating to 1, 2, 3, 6 and 12 months, and only 312 (40%, range 5-61%) cases attended at least two follow-up visits. Only 17 (7%) of all 236 oral treatments (including switches to oral treatment), and 33 (27%) of 123 cases with HIV infection were recorded as designated annual follow-up. Further work is needed to determine factors that account for the wide variation between regions in contact tracing and follow-up performance.
Introduction
This paper accompanies the report on the Case-Notes Audit of diagnosis and treatment of 781 early syphilis cases carried out in 2004 by the National Audit Group in response to increasing numbers of cases of infectious syphilis in the UK. 1 
Methods
The Audit methodology and organization is described in the report on diagnosis and treatment. 1 This part of the Audit provides data that allow comparisons of practice in contact tracing, information giving, follow-up and outcomes to be made between regions, as well as to national averages and National Guidelines. 2 Data aggregated by National Health Service (NHS) Trusts within regions, not published in this paper, have been provided to Chairs of Regional Audit Groups to allow service comparisons between Trusts.
Results

Contact tracing
The Case-Notes Audit asked two questions about contact tracing: 'Was contact tracing carried out' and 'If yes, with whom y .' Therefore, two measures of contact tracing could be calculated: the total number of cases provided with contact tracing; and the number having contact tracing provided by each health-care profession. Table 1 shows performance based on both questions. Of 673 cases who were provided with contact tracing by any health-care professional, 611 (91%) had contact tracing provided by health advisers. It is noteworthy that there is strong agreement between the rates of contact tracing provision obtained in both these questions. Contact tracing identified 997 traceable contacts, and the national ratio of traceable contacts to number of index cases was 1.28 (regional range 0.43-1.79). Table 1 shows the wide range of positive adult contact rates reported, although eight of the 16 regions had positive adult contact rates above 46% (see Discussion).
Information giving
The following are the performances with regard to provision of the information items specified in the National Guidelines: 2 partner notification: 657 (84%, range 61-97), it is noteworthy that this figure agrees with the other two measures of contact tracing described above; health education, 545 (70%, range 46-100) and past treatment, 373 (48%, range 9-78%). Only 45 (6%, range 0-13%) patients were provided with a letter documenting treatment. Table 2 shows performance relating to follow-up. These results are based on a question that asked for specific follow-up intervals. The following number(s) of follow-up visits were recorded: no visits, 179 (23%, range 5-51%); one visit, 275 (35%, range 15-66%); two visits, 80 (10%, range 0-20%); three visits, 173 (22%, range 2-39%); four visits, 21 (3%, range 0-8%); more than four visits, 29 (4%, range 0-12%) and other non-specified follow-up 24 (3%, range 0-8%). There were 127 permutations of follow-up. Only 16 cases (2%) had follow-up at intervals approximating to 1, 2, 3, 6 and 12 months (the minimum follow-up schedule recommended by the National Guidelines 2 ). Table 3 shows the responses to an additional question about eventual follow-up outcomes. Only 36% of cases were ascribed the ideal outcome of a seronegative or serofast non-treponemal test (NTT) titre and discharge at one year, mainly explained by three other responses: failing to return for followup (34%); lifetime annual follow-up (7%) and other reasons (16%). The following other reasons for not achieving this ideal outcome were as follows: follow-up at another centre (34 cases, 4%); negative NTT or serofast at less than 12 months (20 cases, 3%, of whom three cases were discharged); followup for HIV infection (15 cases, 2%); continuing management (14 cases, 2%); other specified nonattendance (11 cases, 1.4%); annual follow-up for five years (six cases, 0.8%), this outcome was reported from one region only; moved away (five cases, 0.6%); negative NTT or serofast at 12 months but not discharged (two cases, 0.3%, one case received an oral treatment, and the other parenteral treatment, both cases had negative tests for HIV infection); and various other responses for 19 (2%) cases (see Discussion for further interpretation of this outcome).
Follow-up
Based on final treatments (after treatment switches), 189 of 236 (80%) cases who received oral treatment and 414 of 513 (81%) cases who received parenteral treatment attended for follow-up. Only 56 cases were designated as requiring annual follow-ups. Of these, 17 (30%), including nine cases with HIV infection, had received oral treatment. Of the remaining 39 parenteral treatments, 24 (62%) were cases with HIV infection. Hence, annual follow-up was only justified for 41 (73%) of these cases. Only 17 (7%) of all 236 oral treatments (including switches to oral treatment) were designated annual follow-up. Only 33 (27%) of 123 cases with HIV infection were recorded as having annual National Guideline outcomes Table 4 shows outcome performance compared against specific standards in the National Guidelines, 2 and against national average performances. A very wide range of resolution rates was recorded across the regions. Nationally, 469 cases were designated as applicable for clinical lesion resolution. Of these, 123 were oral treatments, 327 were parenteral treatments and one received both an oral and parenteral treatment, of whom 97 (79%), 250 (76%) and none, respectively, were recorded as having lesion resolution. The remaining 18 cases comprised eight cases treated elsewhere, six for whom the question about resolution was not answered, three not treated and one case for whom resolution was not known. The low rate of recording a two dilution (fourfold) or greater decrease in NTT titre within 3-6 months after treatment was explained by the following outcomes: failed to reattend (152, 19%); expected titre drop not attained (117, 15%); not tested (26, 3%); other reasons (14, 2%); negative or neat titres at diagnosis (17, 2%) and this question was not answered for (36, 5%) cases. Of the 117 cases not attaining an expected titre drop, 105 (90%) had a follow-up visit at three months and 48 (41%) cases had a follow-up visit at six months.
Recording of treatment completion also displayed a fairly wide performance range of about 30%. Nationally, of the 236 oral treatments (including switches to oral treatment and one case treated with both an oral and parenteral treatment), 195 (83%) were recorded as completed, and of the 513 parenteral treatments, 494 (96%) were recorded as completed. Nationally, 90 (12%) treatments were not recorded as completed, accounted for by the following: no documentation of treatment completion for 42 (5%) cases, 13 (1.7%) cases were not treated based on this measure (note that 14 cases were not treated based on recorded treatments 1 ), 11 (1.4%) cases were treated elsewhere and treatment completion could not be commented on, treatment was not completed in 12 (1.5%) cases, and this question was not answered for 12 (1.5%) cases.
Nationally, 511 adult traceable contacts were recorded as having being seen (at own or other centre), and the range of performance, based on the National Guidelines standard of 60% 2 for the proportion of traceable adults seen, was very wide at around 45%. However, seven regions achieved this standard or greater. Of the 98 cases not provided with contact tracing, 31 traceable contacts were recorded for 15 index cases, of whom six contacts were seen (contacts seen/traceable contacts ¼ 19%). This contrasts with 966 traceable contacts (discounting one outlier with 60 contacts) recorded for 683 index cases for whom contact tracing was provided and where 505 contacts were seen (contacts seen/traceable contacts ¼ 52%).
The national ratio of number of traceable contacts seen to number of index cases was 0.66 (regional range 0.29-0.97).
Discussion
This Audit provides evidence that performance in contact tracing and follow-up of index cases with infectious syphilis in parts of the UK falls short of the recommendations in the National Guidelines. 2 Both the National Guidelines contact tracing performance indicator and the adult positive contact rate were highly variable across the regions. Achievement by seven regions of the National Guidelines contact tracing performance indicator supports the use of this standard. However, none of the aggregated performance rates for the London regions achieved this standard (although nine of the 23 participating London clinics did achieve this standard); the average performance for the London clinics against this standard was 44%. In their paper on contact tracing standards for gonorrhoea and genital chlamydial infection, Low and Radcliffe concluded that 'Standards set using expert opinion are unrealistic when compared with evidence of what is achievable. Evidence based methods should therefore be used to derive outcome standardsy' 3 Might this also be appropriate for infectious syphilis? Nationally, the proportion of adult contacts found to have syphilis was slightly below the rates found in previous studies referred to in the National Guidelines (42 vs. 46 and 60%). 4, 5 However, eight regions achieved rates within or above the range 46-60%. Good agreement between three questions used to measure contact tracing provision suggests that about 15% of cases were not provided with contact tracing. Very little is known about the clinic structures and processes in the UK that support good contact tracing outcomes. Also, improving contact tracing outcomes for infectious syphilis is an effectiveness issue in North America, [6] [7] [8] although little has been published about this in the UK.
The very low rates of recording of a two dilution (four-fold) or greater titre decrease in NTT titres, within 3-6 months after treatment was mainly attributable to patients not attending for follow-up and failure of titre levels to fall. As NTT titres may take longer to decline in early latent syphilis than in primary and secondary syphilis, use of this interval may not be appropriate for early latent syphilis. 9 However, exclusion of early latent cases increased overall performance against this standard from 55% to 59% only. The other NTT titre outcome audited was a seronegative or serofast NTT titre and discharge after one year of follow-up. Table 3 shows performance recorded against this standard for all cases. However, performance against this outcome was really only applicable to 427 cases who had parenteral treatment and who were not known to have HIV infection: based on this denominator, 164 (38%) of these cases met this standard, only a small increase in performance (this denominator also excludes 27 cases who were not treated, were treated elsewhere or where data about treatment was not provided). On the other hand, 327 (42%) cases received an oral treatment and/or had HIV infection, and would not therefore have been eligible for discharge after one year. However, meeting this standard was reported for 111 (34%) of these cases, even though the criteria for discharge were not met.
Based on a range of measures, there appear to be highly variable follow-up rates between regions. Approximately three quarters of index cases attended for follow-up, but only half this number attended for at least two visits. In contrast to the management of gonorrhoea and genital chlamydia, where reducing the number of return visits to clinics may be appropriate, follow-up for serological tests is an essential aspect of management for infectious syphilis. Additionally, this Audit suggests that annual follow-up is not usually provided to cases receiving oral treatment. It is likely that most cases with HIV infection will have continued with follow-up, although this seems to have been poorly documented.
Conclusions and suggested areas for practice improvement/intervention
Further study is needed of UK genitourinary medicine clinic service structures and processes, as well as patient factors, in order to determine factors accounting for wide ranges in contact tracing and follow-up performance. Any possible impact of the current problems in meeting patient demand for services in UK genitourinary medicine clinics 10 on contact tracing and follow-up for cases of infectious syphilis requires urgent attention.
All patients with infectious syphilis should be provided with contact tracing. It is possible that immediate (e.g. dark ground microscopy) or other interventions to achieve early diagnosis may help to facilitate this. Finally, exploration of contact tracing methods to improve outcomes may be warranted in the UK. 
